Search

for
Search:

Sort by

Research

990-1000 / 1000+ results

Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes

research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

93 citations , May 2010 in “European Journal of Cancer”

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

research Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt

83 citations , October 2012 in “International Journal of Oncology”

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

research Nanoparticle systems reduce systemic toxicity in cancer treatment

82 citations , December 2015 in “Nanomedicine”

Nanoparticle systems make cancer treatment less toxic.

research Nonmelanoma skin cancer treated with electronic brachytherapy: Results at 1 year

78 citations , January 2013 in “Brachytherapy”

HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.

Chemotherapy-Induced Dermatological Toxicity: Frequencies and Impact on Quality of Life in Women’s Cancers. Results of a Prospective Study

research Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study

76 citations , August 2007 in “Supportive care in cancer”

Chemotherapy often causes skin, nail, and hair side effects, significantly impacting quality of life.

research Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231

68 citations , January 2013 in “BMC Pharmacology and Toxicology”

Glibenclamide slows breast cancer cell growth by stopping cell division.

Permanent Scalp Alopecia Related to Breast Cancer Chemotherapy by Sequential Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and Docetaxel: A Prospective Study of 20 Patients

research Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients

68 citations , May 2012 in “Annals of Oncology”

Some breast cancer chemotherapy can cause permanent hair loss.

research Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study

65 citations , September 2017 in “British Journal of Cancer”

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

research Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study

59 citations , August 2018 in “The oncologist”

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

research A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment

59 citations , December 2016 in “Supportive Care in Cancer”

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

← Previous page